# Vir Biotechnology's Hepatitis Delta Combination Meets Phase 3 Goal By John Kim Canonical URL: https://www.tokenpost.com/news/business/52376 Published: 2026-11-09T15:07:28.000Z Updated: 2026-11-09T15:07:28.000Z Section: Business > At week 48, 44% of treated patients met the trial’s combined primary endpoint. No patients assigned to delayed treatment had met it at week 12. Vir Biotechnology, Inc. (VIR) announced that its investigational elebsiran and tobevibart combination met the primary endpoint in a Phase 3 hepatitis delta trial, with two further trial readouts expected in 2027. ECLIPSE 1 enrolled 124 adults with chronic hepatitis delta. Patients were assigned two to one to receive monthly injections of the combination or delayed treatment. The primary endpoint required both a hepatitis delta virus (HDV) RNA test showing target not detected and normal levels of alanine aminotransferase (ALT), a liver enzyme. At week 48, 44% of patients receiving the combination met both measures. None of the patients assigned to delayed treatment had met them at week 12, before that group began therapy. The trial also met its key secondary endpoint. HDV RNA target was not detected in 79% of treated patients at week 48, compared with none of the delayed-treatment patients at week 12. One patient had a severe treatment-related drop in neutrophil count, which resolved within 15 days. No patient paused or stopped treatment because of an adverse event. A separate Phase 2 trial, SOLSTICE, followed patients receiving the same combination for longer. HDV RNA target was not detected in all 28 patients who completed 96 weeks of treatment. Ten patients stopped treatment. All 10 maintained the response for at least 12 weeks afterward. That off-treatment analysis is preliminary and exploratory, and follow-up continues. Vir expects [ECLIPSE 2 and ECLIPSE 3 results]() in the first quarter of 2027. ## Links in this article - [ECLIPSE 2 and ECLIPSE 3 results](https://www.tokenpost.com/news/business/49907)